VGX International Signs a Master Product Sale Agreement with BioCancell Therapeutics of Israel to Supply Plasmid for Its Multiple Clinical Programs
Published: Oct 27, 2008
THE WOODLANDS, Texas--(BUSINESS WIRE)--VGXI, Inc. today announced the execution of a Master Product Sale Agreement to supply plasmid between its parent company, VGX International, and BioCancell Therapeutics. BioCancell is a biopharmaceuticals corporation specializing in the development of Patient-Oriented, Targeted Therapy for the treatment of numerous types of cancer. Products under the Agreement will be manufactured at the VGXI, Inc production facility in The Woodlands, TX.